Synthesis and Selective Cyclooxygenase-2 Inhibitory Activity of a Series of Novel, Nitric Oxide Donor-Containing Pyrazoles

Journal of Medicinal Chemistry

Volumn 47, Issue 9, 2004, Pages 2180-2193

  Ranatunge, Ramani R ^a   Augustyniak, Michael ^a   Bandarage, Upul K ^a   Earl, Richard A ^a   Ellis, James L ^a   Garvey, David S ^a   Janero, David R ^a   Letts, L Gordon ^a   Martino, Allison M ^a   Murty, Madhavi G ^a   Richardson, Stewart K ^a   Schroeder, Joseph D ^a   Shumway, Matthew J ^a   Tam, S William ^a   Trocha, A Mark ^a   Young, Delano V ^a  

^a NitroMed Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 CYCLOHEXYL 3 [1 (HYDROXYIMINO) 4 (NITROOXY)BUTYL]PYRAZOL 5 YL] 4 (METHYLSULFONYL)BENZENE; 1 [3 [4 (NITROOXY)BUT 1 ENYL] 1 CYCLOHEXYLPYRAZOL 5 YL] 4 (METHYLSULFONYL)BENZENE; 4 [1 CYCLOHEXYL 3 [3 (NITROOXY)PROPYL]PYRAZOL 5 YL] 1 (METHYLSULFONYL)BENZENE; ACETYLSALICYLIC ACID; BENZENE DERIVATIVE; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NITRIC OXIDE; OXIME; PYRAZOLE DERIVATIVE; TERT BUTOXY N (CYCLOPENTYLAMINO)CARBOXAMIDE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; GASTRITIS; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; NITRATES; NITRIC OXIDE DONORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 11144354316     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030276s     Document Type: Conference Paper

References (51)

1. Skoutakis, V. A.; Carter, C. A.; Micklee, T. R.; Smith, V. H.; Arkin, C. R.; Allissantros, J.; Petty, D. A. Review of Diclofenac and Evaluation of Its Place in Therapy as a Nonsteroidal Antiinflammatory Agent. Drug Intell. Clin. Pharm. 1988, 3, 850-859.
2. Lombardino, G. Non Steroidal Antiinflammatory Drugs; John Wiley & Sons: New York, 1985.
3. Dannhard, G.; Kiefer, W. Cyclooxygenase inhibitors-current status and future prospects. Eur. J. Med. Chem. 2001, 36, 109-126.
4. Carter, J. S. Inhibitors of cyclooxygenase-2: November 1999 - April 2000. Exp. Opin. Ther. Pat. 2000, 10, 1011-1020.
5. Talley, J. J. Selective Inhibitors of Cyclooxygenase-2 (COX-2). Prog. Med. Chem. 1999, 36, 201-234.
6. Xie, W.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expressions of a mitogen-responsive gene encoding prostaglandin synthase regulated by mRNA splicing. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 2692-2696.
7. Kujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; Herschman, H. R. TISIO, a Phorbol Ester Tumor Promoter-Inducible mRNA from Swiss 3T3 Cells, Encodes a Novel Prostaglandin Synthase/Cyclooxygenase Homolog. J. Biol. Chem. 1991, 266, 12866-12872.
8. Chan, C.-C.; Boyce, S.; Brideau, C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J.; Ford-Hutchinson, A. W.; Forrest, M. J.; Gauthier, J. Y.; Gordon, R.; Gresser, M.; Guay, J.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Patrick, D.; Percival, M. D.; Perrier, H.; Prasit, P.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Visco, D.; Wang, Z.; Webb, J.; Wong, E.; Xu, L. J.; Young, R. N.; Zamboni, R.; Rienddeau, D. Rofecoxib [Vioxx, MK-0966; 4-4′ -methylsulfonylphenyl]-3-phenyl-2-(5H)-furanone]; a Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles. J. Pharmacol. Exp. Therap. 1999, 290, 551-560.
9. Hinz, B.; Brune, K. Cyclooxygenase-2 10 Years Later. J. Pharm. Exp. Therap. 2002, 300, 367-375.
10. DeWitt, D. L. COX-2 Selective Inhibitors: the New Super Aspirins. Mol. Pharmacol. 1999, 55, 625-631.
11. Mitchell, J. A.; Akarasereenont, P.; Thiemermann, C.; Flower, R. J.; Vane, J. R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 11693-11697.
12. Fries, J. F. NSAID Gastropathy: Epidemiology. J. Musculoskeletal Med. 1991, 8, 21-28.
13. For a review, see: Reitz, D. B.; Seibert, K. Selective Cyclooxygenase Inhibitors. Annu. Rep. Med. Chem. 1995, 30, 179-188.
14. For a review, see: Prasit, P.; Riendeau, D. Selective Cyclooxygenase-2 Inhibitors. Annu. Rep. Med. Chem. 1997, 32, 211-220.
15. (a) Penning, T. D.; Tally, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Doctor, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
16. (b) Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.-C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y. ; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Therien, M.; Vikers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N., Forrest, M.; Visco, D.; Patrick, D. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′ -methylsulfonylphenyl)-3-phenyl-2 (5H0-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
17. (a) Meyer-Kirchrath, J.; Schror, K. Cyclooxygenase-2 Inhibition and Side-effects of Nonsteroidal Antiinflammatory Drugs in Gastrointestinal Tract. Curr. Med. Chem. 2000, 7, 1121-1129.
18. (b) Catella-Lawson, F.; Crofford, L. J. Cyclooxygenase inhibitors and thrombogenicity. Am. J. Med. 2001, 110, 28S-32S.
19. Mukherjee, D.; Nissen, S. E.; Topol, E. J. Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors. JAMA. 2001, 286, 954-959.
20. Hawkey, C. J. COX-2 Inhibitors. Lancet. 1999, 353, 307-314.
21. (a) Wolfe, M. M.; Lichtenstein, D. R.; Singh, G. Gastrointestinal Toxicity of Non Steroidal Antiinflammatory Drugs. N. Engl. J. Med. 1999, 340, 1888-1899.
22. (b) Deeks, J. J.; Smith, L. A.; Bradley, M. D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. Br. Med. J. 2002, 325, 619-627.
23. Wallace, J. L.; Reuter, B.; Cicala, C.; McKnight, W.; Cirino, G.; Gisham, M. B. Novel Nonsteroidal Antiinflammatory Drug Derivatives with Markedly Reduced Ulcerogenic Properties in Rats. Gastroenterology 1994, 107, 173-179.
24. Wallace, J. L.; Reuter, B.; Cicala, C.; McKnight, W.; Grisham, M. B.; Cirino, G. A Diclofenac Derivative without Ulcerogenic Properties. J. Pharmacol. 1994, 257, 249-255.
25. Elliott, S. N.; McKnight, W.; Cirino, G.; Wallace, J. L. A Nitric Oxide-releasing Nonsteroidal Antiinflammatory Drug Accelerates Gastric Ulcer Healing in Rats. Gastroenterology 1995, 109, 524-530.
26. Muscara, M. N.; McNight, W.; Del Soldato, P.; Wallace, J. L. Effects of a Nitric Oxide-Releasing Naproxen Derivative on Hypertension and Gastric Damage Induced by Chronic Nitric Oxide Inhibition in the Rat. Pharmacol. Lett. 1998, 62, 235-240.
27. (a) Wallace, J. L.; Reuter, B.; Cirino, G. Nitric Oxide-releasing Nonsteroidal Antiinflammatory Drugs: Novel Approach for Reducing Gastrointestinal Toxicity. J. Gastroenterol. Hepatol. 1994, 9, S40-S44.
28. (b) Kartasasmita, R. E.; Laufer, S.; Lehmann, J. NO-Donors (VII [I]): Synthesis and Cyclooxygenase Inhibitory Properties of N- and S-Nitrooxypivaloyl-cysteine Derivatives of Naproxen - A Novel Type of No-NSAID. Arch. Pharm. Pharm. Med. Chem. 2002, 335, 363-366.
29. Bandarage, U. K.; Janero, D. R.; Nitric Oxide-releasing Nonsteroidal Antiinflammatory Drugs: Novel Gastrointestinal Sparing Drugs. Mini-Rev. Med. Chem. 2000, 1, 57-70.
30. (a) Bandarage, U. K.; Chen, L.; Fang, X.; Garvey, D. S.; Glavin, A.; Janero, D. R.; Letts, L. G.; Mercer, G. J.; Saha, J. K.; Schroeder, J. D.; Shumway, M. J.; Tam, S. W. Nitrosothiol Esters of Diclofenac: Synthesis and Pharmacological Chracterization as Gastrointestinal-Sparing Prodrugs. J. Med. Chem. 2000, 43, 4005-4016.
31. (b) Cena, C.; Lolli, M. L.; Lazzarato, L.; Guaita, E.; Morini, G.; Coruzzi, G.; McElroy, S.; Megson, I.; Fruttero, R.; Gasco, A. Antiinflammatory, Gastrosparing, and Antiplatelet Properties of New NO-Donor Esters of Aspirin. J. Med. Chem. 2003, 46, 747-754.
32. (c) Bandarage, U. K.; Dong, Q.; Fang, X.; Garvey, D. S.; Mercer, G. J.; Richardson, S. K.; Schroeder, J. D.; Wang, T. Preparation and Activity of Nitrosated and Nitrosylated Nonsteroidal Antiinflammatory Compounds. US 99-429019. CAN 135: 288343. AN 2001: 721438.
33. Gries, A.; Bode, C.; Peter, K.; Herr, A.; Böhrer, H.; Motsch, J.; Martin, E. Inhaled Nitric Oxide Inhibits Human Platelet Aggregation, P-Selectin Expression, and Fibrinogen Binding In Vitro and In Vivo. Circulation 1998, 97, 1481-1487.
34. Nong, Z.; Hoylaerts, M.; Pelt, N. V.; Collen, D.; Janssens, S. Nitric Oxide Inhalation Inhibits Platelet Aggregation and Platelet-Mediated Pulmonary Thrombosis in Rats. Circ. Res. 1997, 81, 865-869.
35. (a) Bandarage, R. R.; Augustyniak, M. E.; Bandarage, U. K.; Cochran, E. D.; Earl, R. A.; Garvey, D. S.; Janero, D. R.; Letts, L. G.; Marek, P.; Martino, A. M.; Murty, M. G.; Richardson, S. K.; Schroeder, J. D.; Shumway, M. J.; Tam, S. W.; Trocha, A. M.; Young, D. V. Synthesis and COX-2 Inhibitory Activity of a Series of Novel Pyrazoles. Presented at the 224th American Chemical Society National Meeting, Boston, MA, Aug 18-22, 2002; abstract no. 314.
36. (b) Bandarage, R. R.; Bandarage, U. K.; Fang, X.; Garvey, D. S.; Letts, L. G.; Schroeder, J. D.; Tam, S. W. Preparation of Nitrosated and Nitrosylated Cyclooxygenase-2 Inhibitors. PCT Int. Appl. 2001, WO 0145703 A1 20010628.
37. Kanth, J. V. B.; Brown, H. C. Hydroboration. 97. Synthesis of New Exceptional Chloroborane-Lewis Base Adducts for Hydroboration. Dioxane-Monochloroborane as a Superior Reagent for the Selective Hydroboration of Terminal Alkenes. J. Org. Chem. 2001, 66, 5359-5365.
38. Adamczyk, M.; Johnson, D. D.; Reddy, R. E. Bone Collagen Cross Links: A Convergent Synthesis of (+)-Deoxypyrrolidine. J. Org. Chem. 2001, 66, 11-19.
39. 2A1Cl-MeONHMe·HCl. Tetrahedron Lett. 1997, 38, 2685-2688.
40. Nemoto, H.; Nagamochi, M.; Ishibashi, H.; Fukumoto, K. A Remarkable Substituent Effect on the Enantioselectivity of Tandem Asymmetric Epoxidation and Enantiospecific Ring Expansion of Cyclopropylidene Alcohols: A New Enantiocontrolled Synthesis of (-)-Debromoaplysin and (-)-Aplysin. J. Org. Chem. 1994, 59, 74-79.
41. Sabitha, G.; Syamala, M.; Yadav, J. S. A Mild, Efficient, Inexpensive, and Selective Cleavage of Primary tert-Butyldimethylsilyl Ethers by Oxone in Aqueous Methanol. Org. Lett. 1999, 1, 1701-1703.
42. Wang, P. G.; Xian, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, J. Nitric Oxide Donors: Chemical Activities and Biological Applications. Chem. Rev. 2002, 102, 1091-1134.
43. Kerr, D. E.; Kissinger, L. F.; Shoyab, M. Cyclohexane Diester Analogues of Phorbol Ester as Potential Activators of Protein Kinase C. J. Med. Chem. 1990, 33, 1958-1962.
44. Blackburn, L.; Pei, C.; Taylor, R. J. K. In situ Alcohol Oxidation-Wittig Reactions Using Non-Stabilized Phosphoranes. Syn Lett. 2002, 2, 215-218.
45. Brown, D. L.; Graneto, M. J.; Ludwig, C. L.; Talley, J. J. 2-Fluorobenzenesulfonyl Compounds for the Treatment of Inflammation, WO 01/81332, 2001.
46. Young, J. M.; Panah, S.; Satchawatcharaphong, C.; Cheung, P. S. Human Whole Blood Assays for Inhibition of Prostaglandin G/H Synthases-1 and -2 Using A23187 and Lipopolysaccharide Stimulation of Thromboxane B2 Production. Inflamm. Res. 1996, 45, 246-253.
47. Glaser, K.; Sung, M. L.; O'Neill, K.; Belfast, M.; Hartman, D.; Carlson, R.; Kreft, A.; Kubrak, D.; Hsiao, C. L.; Weichman, B. Etodolac Selectivity Inhibits Human Prostaglandin G/H Synthase 2 (PGHS-2) versus Human PGHS-1. Eur. J. Pharmacol. 1995, 281, 107-109.
48. Seibert, K.; Zhang, Y.; Leahy, K.; Hauser, S.; Masferrer, J.; Perkins, W.; Lee, L.; Isakson, P. Pharmacological and Biochemical Demonstration of Cyclooxygenase 2 in Inflammation and Pain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91 (25), 12013-12017.
49. (a) Sedgwick, A. D.; Lees, P. Studies of Eicosanoid Production in the Air Pouch Model of Synovial Inflammation. Agents Actions, 1986, 18, 429-438.
50. (b) Masferrer, J. L.; Zweifel, B. S.; Manning, P. T.; Hauser, S. D.; Scott, D.; Leahy, K. M.; Smith, W. G.; Isakson, P. C.; Seibert, K. Selective Inhibition of Inducible Cyclooxygenase 2 in vivo is Antiinflammatory and Nonulcerogenic. Proc. Natl. Acad. Sci., U.S.A. 1994, 91, 3228-3232.
51. Ghali, N. I.; Venton, D. L.; Hung, S. C.; Le Breton, G. C. A High-Yielding Synthesis of Monoalkylhdyrazines. J. Org. Chem. 1981, 46, 5413-5414.